ArticleJournal of gastroenterology2014
C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma.
Article in Journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Genome-wide analysis of colorectal cancer based on gene-based somatic copy number alterations during neoplastic progression within the same tumor.Cancer medicine · 2023Article
- Article
- Effects of hsa-mir-145-5p on the Regulation of msln Expression in Colorectal Adenocarcinoma.Analytical cellular pathology (Amsterdam) · 2022Article
- Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model.Investigational new drugs · 2021Article
- Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma.Oncology letters · 2021Article
- Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors.Biomedicines · 2021Article
- Article
- Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors.Archives of medical science : AMS · 2021Article
- Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.Pathology oncology research : POR · 2020Article
- Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer.Oncology letters · 2020Article
- Mesothelin expression and its prognostic role according to microsatellite instability status in colorectal adenocarcinoma.Medicine · 2019Article
- Mesothelin expression has prognostic value in stage ΙΙ/ΙΙΙ colorectal cancer.Virchows Archiv : an international journal of pathology · 2019Article
- Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors.EBioMedicine · 2017Article
- Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer.Journal of Cancer · 2017Article
- Article
- Aberrant Expression of Calretinin, D2-40 and Mesothelin in Mucinous and Non-Mucinous Colorectal Carcinomas and Relation to Clinicopathological Features and Prognosis.Pathology oncology research : POR · 2016Article
- Clinical impacts of mesothelin expression in gastrointestinal carcinomas.World journal of gastrointestinal pathophysiology · 2016Review
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.Cancer discovery · 2016Review
- Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.Oncotarget · 2015Article
- Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms.Oncology letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymph node metastasis is a key event of colorectal cancer (CRC) progression. Mesothelin is expressed in various types of malignant tumor and associated with an unfavorable prognosis. The full-length mesothelin (Full-ERC) is cleaved by protease into membrane-bound C-ERC/mesothelin and N-ERC/mesothelin which is secreted into the blood. The aim of this study was to examine the biological role of mesothelin in CRC by clinicopathological analysis and in vitro lymphatic invasion assay.
methodsNinety-one cases of CRC specimens were immunohistochemically examined and the localization of mesothelin in luminal membrane and/or cytoplasm was also evaluated. Lymphatic invasion assay was also performed using the human CRC cell line, WiDr, which was transfected with Full-, N- and C-ERC/mesothelin expression plasmids (Full-WiDr, N-WiDr and C-WiDr).
resultsImmunohistochemically, "luminal membrane positive" of mesothelin was identified in 37.4 %, and correlated with lymphatic permeation and lymph node metastasis, but not with patients' prognosis. Interestingly, among the patients with lymph node metastasis (N = 38), "luminal membrane positive" of mesothelin significantly correlated with unfavorable patients' outcome. In addition, lymphatic invasion assay revealed that Full-WiDr and C-WiDr more significantly invaded human lymphatic endothelial cells than the Mock-WiDr (P < 0.01).
conclusionThe luminal membrane expression of mesothelin was associated with unfavorable prognosis of CRC patients with lymph node metastasis. Moreover, this is the first report to prove the biological function of C-ERC/mesothelin associated with lymphatic invasion of cancer in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.